Anti-diabetic effect of portulaca oleracea l. Polysaccharideandits mechanism in diabetic rats

International Journal of Molecular Sciences

Volumn 17, Issue 8, 2016, Pages

  Bai, Yu ^a   Zang, Xueli ^b   Ma, Jinshu ^c   Xu, Guangyu ^d  

^a JILIN UNIVERSITY   (China)

^b Changchun Medical College   (China)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^d BEIHUA UNIVERSITY   (China)

Author keywords

Anti diabetic; Polysaccharide; Purslane

Indexed keywords

ANTIDIABETIC AGENT; ARABINOSE; GALACTOSE; GLIBENCLAMIDE; GLUCOSE; INTERLEUKIN 6; MANNOSE; PORTULACA OLERACEA EXTRACT; RHAMNOSE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; XYLOSE; GLUCOSE BLOOD LEVEL; PLANT EXTRACT; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; NONHUMAN; RAT; WESTERN BLOTTING; ANALYSIS; ANIMAL; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; INSULIN RESISTANCE; MALE; METABOLISM; PORTULACA; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; PLANT EXTRACTS; PORTULACA; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84979530270     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17081201     Document Type: Article

References (44)

1. Westerhaus, B.; Gosmanov, A.R.; Umpierrez, G.E. Diabetes prevention: Can insulin secretagogues do the job? Prim. Care Diabetes 2011, 5, 73-80. [CrossRef] [PubMed]
2. Defronzo, R.A. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58, 773-795. [CrossRef] [PubMed]
3. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053. [CrossRef] [PubMed]
4. Kitabchi, A.E.; Temprosa, M.; Knowler, W.C. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: Effects of life style intervention and metformin. Diabetes 2005, 54, 2404-2414. [PubMed]
5. Inzucchi, S.E. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 2002, 287, 360-372. [CrossRef] [PubMed]
6. Xiang, A.H.; Peters, R.K.; Kjos, S.L.; Goico, J.; Ochoa, C.; Marroquin, A.; Tan, S.; Hodis, H.N.; Azen, S.P.; Buchanan, T.A. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: Impact on glucose tolerance and β-cell function. J. Clin. Endocrinol. Metab. 2004, 89, 2846-2851. [CrossRef] [PubMed]
7. Mann, J.F.; Schmieder, R.E.; McQueen, M.; Dyal, L.; Schumacher, H.; Pogue, J.; Wang, X.; Maggioni, A.; Budaj, A.; Chaithiraphan, S., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372, 547-553. [CrossRef]
8. Nissen, S.E.; Wolsk, I.K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356, 2457-2471. [CrossRef] [PubMed]
9. Scarpello, J.H.; Hodgson, E.; Howlett, H.C. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet. Med. 1998, 15, 651-656. [CrossRef]
10. Owen, M.R.; Doran, E.; Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348, 607-614. [CrossRef] [PubMed]
11. Zhen, Z.Y.; Wei, L.; Feng, Z. Deciphering the therapeutic mechanisms of Xiao-Ke-An in treatment of type 2 diabetes in mice by a Fangjiomics approach. Acta Pharmacol. Sin. 2015, 36, 699-707.
12. Li, W.L.; Zheng, H.C.; Bukuru, J.; de Kimpe, N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J. Ethnopharmacol. 2004, 92, 1-21. [CrossRef] [PubMed]
13. Liu, J.P.; Zhang, M.; Wang, W.Y.; Grimsgaard, S. Chinese herbal medicines for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2004, 3, 1-3 CD003642. [PubMed]
14. Xie, W.; Xing, D.; Sun, H.; Wang, W.; Ding, Y.; Du, L. The effects of Ananas comosus L. leaves on diabetic-dyslipidemic rats induced by alloxan and a high-fat/high-cholesterol diet. Am. J. Chin. Med. 2005, 33, 95-105. [CrossRef] [PubMed]
15. Xie, W.; Zhang, Y.; Wang, N.; Zhou, H.; Du, L.; Ma, X.; Shi, X.; Cai, G. Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice. Eur. J. Pharmacol. 2008, 599, 159-165. [CrossRef] [PubMed]
16. Xie, W.D.; Zhao, Y.N.; Du, L.J.; Cai, G.P. Scorpion in combination with Gypsum: Novel antidiabetic activities in streptozotocin-induced diabetic mice by up-regulating pancreatic PPARγ and PDX-1 expressions. Evid. Based Complement. Altern. Med. 2011, 2011, 683561. [CrossRef] [PubMed]
17. Chauhan, B.S.; Johnson, D.E. Seed germination ecology of Portulaca oleracea L.: An important weed of rice and upland crops. Ann. Appl. Biol. 2009, 155, 61-69. [CrossRef]
18. Lee, J.; Chauhan, B.S.; Johnson, D.E. Germination of fresh horse purslane (Trianthema portulacastrum) seeds in response to different environmental factors. Weed Sci. 2011, 59, 495-499. [CrossRef]
19. D’Andrea, R.M.; Andreo, C.S.; Lara, M.V. Deciphering the mechanisms involved in Portulaca oleracea (C4) response to drought: Metabolic changes including crassulacean acid-like metabolism induction and reversal upon re-watering. Physiol. Plant. 2014, 152, 414-430. [CrossRef] [PubMed]
20. Uddin, M.K.; Juraimi, A.S.; Hossain, M.S. Purslane weed (Portulaca oleracea): A prospective plant source of nutrition, omega-3 fatty acid, and antioxidant attributes. Sci. World J. 2014, 2014. [CrossRef] [PubMed]
21. Zhao, R.; Zhang, T.; Zhao, H. Effects of Portulaca oleracea L. polysaccharides on phenotypic and functional maturation of murine bone marrow derived dendritic cells. Nutr. Cancer 2015, 67, 987-993. [CrossRef] [PubMed]
22. Zhou, Y.X.; Xin, H.L.; Rahman, K.; Wang, S.-J.; Peng, C.; Zhang, H. Portulaca oleracea L.: A review of phytochemistry and pharmacological effects. BioMed Res. Int. 2015, 2015. [CrossRef] [PubMed]
23. Meng, Y.; Ying, Z.; Xiang, Z.; Hao, D.; Zhang, W.; Zheng, Y.; Gao, Y.; Ying, X. The anti-inflammation and pharmacokinetics of a novel alkaloid from Portulaca oleracea L. J. Pharm. Pharmacol. 2016, 68, 397-405. [CrossRef] [PubMed]
24. Rahdari, P.; Hosseini, S.M.; Tavakoli, S. The studying effect of drought stress on germination, proline, sugar, lipid, protein and chlorophyll content in purslane (Portulaca oleracea L.) leaves. J. Med. Plants Res. 2012, 6, 1539-1547.
25. Lee, A.S.; Lee, Y.J.; Lee, S.M.; Yoon, J.J.; Kim, J.S.; Kang, D.G.; Lee, H.S. Portulaca oleracea ameliorates diabetic vascular inflammation and endothelial dysfunction in db/db mice. Evid. Based Complement. Altern. Med. 2012, 2012. [CrossRef] [PubMed]
26. Gong, F.; Li, F.; Zhang, L.; Li, J.; Zhang, Z.; Wang, G. Hypoglycemic effects of crude polysaccharide from Purslane. Int. J. Mol. Sci. 2009, 10, 880-888. [CrossRef] [PubMed]
27. El-Sayed, M.I.K. Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. J. Ethnopharmacol. 2011, 137, 643-651. [CrossRef] [PubMed]
28. Winzell, M.S.; Ahren, B. The high-fat diet-fed mouse: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 2004, 53, 215-219. [CrossRef]
29. Leinonen, E.; Hurt-Camejo, E.; Wiklund, O.; Hultén, L.M.; Hiukka, A.; Taskinen, M.R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003, 166, 387-394. [CrossRef]
30. Spranger, J.; Kroke, A.; Mohlig, M.; Hoffmann, K.; Bergmann, M.M.; Ristow, M.; Boeing, H.; Pfeiffer, A.F. Inflammatory cytokines and the risk to develop type 2 diabetes. Diabetes 2003, 52, 812-817. [CrossRef] [PubMed]
31. Ruan, H.; Hacohen, N.; Golub, T.R.; van Parijs, L.; Lodish, H.F. Tumor necrosis factor-α suppresses adipocytes-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: Nuclear factor-κB activation by TNF-α is obligatory. Diabetes 2002, 51, 1319-1336. [CrossRef] [PubMed]
32. Naguib, G.; Al-Mashat, H.; Desta, T.; Graves, D.T. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J. Investig. Dermatol. 2004, 123, 87-92. [CrossRef] [PubMed]
33. Lee, H.B.; Yu, M.R.; Yang, Y.Q. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14, 241-245. [CrossRef]
34. Susztak, K.; Raff, A.C.; Schiffer, M. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55, 225-233. [CrossRef] [PubMed]
35. Koren, S.; Fantus, I.G. Inhibition of the protein tyrosine phosphatase PTP1B: Potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21, 621-640. [CrossRef] [PubMed]
36. Wang, N.; Zhang, D.; Mao, X.; Zou, F.; Jin, H.; Ouyang, J. Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetes. Mol. Cell. Endocrinol. 2009, 307, 89-98. [CrossRef] [PubMed]
37. Tamrakar, A.K.; Maurya, C.K.; Rai, A.K. PTP1B inhibitors for type 2 diabetes treatment: A patent review (2011-2014). Expert Opin. Ther. Pat. 2014, 24, 1101-1115. [CrossRef] [PubMed]
38. Pan, D.; Wang, L.; Hu, B.; Zhou, P. Structural characterization and bioactivity evaluation of an acidic proteoglycan extract from Ganoderma lucidum fruiting bodies for PTP1B inhibition and anti-diabetes. Biopolymers 2014, 101, 613-623. [CrossRef] [PubMed]
39. Davis, J.A.; Sharma, S.; Mittra, S.; Sujatha, S.; Kanaujia, A.; Shukla, G.; Katiyar, C.; Lakshmi, B.S.; Bansal, V.S.; Bhatnagar, P.K. Antihyperglycemic effect of Annona squamosa hexane extract in type 2 diabetes animal model: PTP1B inhibition, a possible mechanism of action? Indian J. Pharmacol. 2012, 44, 326-332. [CrossRef] [PubMed]
40. Sun, Y.X.; Wang, S.S.; Li, T.B.; Li, X.; Jiao, L.; Zhang, L. Purification, structure and immunobiological activity of a new water-soluble polysaccharide from the mycelium of Polyporus albicans (Imaz.) teng. Bioresour. Technol. 2008, 99, 900-904. [CrossRef] [PubMed]
41. Dubois, M.; Gilles, K.A.; Hamilton, J.K.; Gilles, K.A.; Hamilton, J.K.; Rebers, P.A.; Smith, F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956, 28, 350-356. [CrossRef]
42. Lowry, O.H.; Farr, A.L.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin-Phenol reagents. J. Biol. Chem. 1951, 193, 265-275. [PubMed]
43. Filisetti-Cozzi, T.M.; Carpita, N.C. Measurement of uronic acids without interference from neutral sugars. Anal. Biochem. 1991, 197, 157-162. [CrossRef]
44. Lehrfeld, J. Simultaneous gas-liquid chromatographic determination of aldonic acids and aldoses. Anal. Chem. 1985, 57, 346-348. [CrossRef]